Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Woo

Showing results (1-10 of 54) with videos related to

Pageof 6
Sort By:
Clinical Orthopaedics and Related Research|November 8, 2012
Adverse events after recombinant human BMP2 in nonspinal orthopaedic proceduresEmily Jane Woo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2014
Allergic reactions after egg-free recombinant influenza vaccine: reports to the US Vaccine Adverse Event Reporting SystemEmily Jane Woo
The Spine Journal : Official Journal of the North American Spine Society|December 18, 2013
Postmarketing safety of biologics and biological devicesEmily Jane Woo
The Spine Journal : Official Journal of the North American Spine Society|October 27, 2012
Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience databaseEmily Jane Woo
Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons|December 20, 2011
Adverse events reported after the use of recombinant human bone morphogenetic protein 2Emily Jane Woo
Vaccine|June 6, 2022
Thrombocytopenia after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting systemEmily Jane Woo, Rositsa B Dimova
Pediatric Surgery International|June 30, 2006
Intrauterine gastric perforationJane Woo, Thomas Eusterbrock, Sunghoon Kim
Vaccine|January 15, 2022
Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting SystemEmily Jane Woo, Pedro L Moro
Vaccine|March 8, 2021
Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting systemEmily Jane Woo, Pedro L Moro
Drug Safety|May 25, 2013
Application of information retrieval approaches to case classification in the vaccine adverse event reporting systemTaxiarchis Botsis, Emily Jane Woo, Robert Ball
Pageof 6

Showing results (1-10 of 54) with videos related to

Sort By:
Pageof 6
Clinical Orthopaedics and Related Research|November 8, 2012
Adverse events after recombinant human BMP2 in nonspinal orthopaedic proceduresEmily Jane Woo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2014
Allergic reactions after egg-free recombinant influenza vaccine: reports to the US Vaccine Adverse Event Reporting SystemEmily Jane Woo
The Spine Journal : Official Journal of the North American Spine Society|December 18, 2013
Postmarketing safety of biologics and biological devicesEmily Jane Woo
The Spine Journal : Official Journal of the North American Spine Society|October 27, 2012
Recombinant human bone morphogenetic protein-2: adverse events reported to the Manufacturer and User Facility Device Experience databaseEmily Jane Woo
Journal of Oral and Maxillofacial Surgery : Official Journal of the American Association of Oral and Maxillofacial Surgeons|December 20, 2011
Adverse events reported after the use of recombinant human bone morphogenetic protein 2Emily Jane Woo
Vaccine|June 6, 2022
Thrombocytopenia after Ad.26.COV2.S COVID-19 vaccine: Reports to the vaccine adverse event reporting systemEmily Jane Woo, Rositsa B Dimova
Pediatric Surgery International|June 30, 2006
Intrauterine gastric perforationJane Woo, Thomas Eusterbrock, Sunghoon Kim
Vaccine|January 15, 2022
Postmarketing safety surveillance of high-dose quadrivalent influenza vaccine: Reports to the Vaccine Adverse Event Reporting SystemEmily Jane Woo, Pedro L Moro
Vaccine|March 8, 2021
Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting systemEmily Jane Woo, Pedro L Moro
Drug Safety|May 25, 2013
Application of information retrieval approaches to case classification in the vaccine adverse event reporting systemTaxiarchis Botsis, Emily Jane Woo, Robert Ball
Pageof 6